Clear-cell carcinoma of the ovary

Fujiwara, Keiichi; Shintani, Daisuke; Nishikawa, Tadaaki

doi:10.1093/annonc/mdw086

Cited by 86 publications

(60 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,10 OCCC is rarely bilateral, and patients are usually diagnosed at an early stage. 11 Histologic features of OCCC are characterized by solid, papillary, and tubulocystic patterns. 12 Most OCCCs are presumed to arise from endometriotic cysts, 13 and key driver events involving HN-F1B overexpression and somatic ARID1A mutations have been identified.…”

Section: Discussionmentioning

confidence: 99%

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Yauy¹,

Imbert‐Bouteille²,

Bubien³

et al. 2019

J Natl Compr Canc Netw

View full text Add to dashboard Cite

This report presents the case of a 28-year-old woman diagnosed with a left adnexal mass in the context of pelvic pain that appeared 2 months earlier. First ultrasonography revealed a 4-cm pelvic mass suspected to be a uterine fibroid. Pelvic MRI showed a 10-cm left adnexal mass with a polylobed aspect, associated with a cystic portion that had a mucinous borderline epithelial part. The patient's CA 125 level was 237 UI/mL and carcinoembryonic antigen level was 37.6 ng/mL.

show abstract

Section: Discussionmentioning

confidence: 99%

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Yauy¹,

Imbert‐Bouteille²,

Bubien³

et al. 2019

J Natl Compr Canc Netw

View full text Add to dashboard Cite

show abstract

“…Furthermore, OCCC is known to be associated with endometriosis and atypical adeno broma with a relative risk of 12.5% [13]. Endometriosis is a condition of ectopic endometrial tissue, o en resulting in infertility.…”

Section: Discussionmentioning

confidence: 99%

“…Endometriosis is a condition of ectopic endometrial tissue, o en resulting in infertility. Although rare, 2.5% of ovarian endometriosis cases result in malignant transformation mostly due to K-ras associated mutation and o en are diagnosed at a relatively early age [13,14]. ese patients o en have a better prognosis than women with malignant ovarian cancer without endometriosis [15].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Ovarian Clear Cell Carcinoma in the Context of In Vitro Fertilization Pregnancy

Inamdar

Fulginiti

Yiu

et al. 2020

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

Adnexal masses are routinely encountered in the clinical practice. However, adnexal masses during pregnancy are incidental findings and usually resolve spontaneously or can be managed conservatively during pregnancy due to their benign nature. Ovarian malignancy is a rare event to occur during pregnancy. Only a few cases of ovarian clear cell carcinoma (OCCC), a subtype of epithelial ovarian cancers, have been reported in pregnancy and all of which have undergone cystectomy or pregnancy termination prior to the last trimester of pregnancy. We present a unique case of OCCC in a pregnant 38-year old female of Asian ethnicity with endometriosis and an in vitro fertilization (IVF) pregnancy. The OCCC, initially suspected to be of benign nature, was removed via emergency cesarean section during delivery in the late preterm period. The Positron Emission Tomography scan performed a few weeks after delivery confirmed metastatic lesions. Our case study not only emphasizes the need for definitive treatment option for endometriosis but also a close surveillance of all masses diagnosed during pregnancy, in particular with a background of other risk factors such as endometriosis and Asian ethnicity. In addition, our study advocates the need for the guidelines for management of such rare cases.

show abstract

“…2 Ovarian clear cell carcinoma (OCCC) has unique features, and has an incidence of 23% in Japan, but at most 10% in North America and Europe. 3 Thus, OCCC is categorized as a rare gynecologic disease. The molecular background of OCCC is unique, since the tumor is usually negative for p53 mutations, despite these being common in high-grade EOC, and positive for ARID1A and/or PIK3CA mutations.…”

Section: Introductionmentioning

confidence: 99%

Current and future strategies for treatment of ovarian clear cell carcinoma

Ogasawara

Sato

2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Ovarian clear cell carcinoma (OCCC) is one of the five histological types of epithelial ovarian cancer (EOC). OCCC comprises 23% of all EOC cases in Japan, whereas the rate of OCCC in North America and Europe is much lower. OCCC is generally categorized as a rare gynecologic malignancy, and there is limited evidence for specific treatment. The clinical basis for treatment of OCCC is mostly based on retrospective studies, many of which were performed in Japan. Until recently, most randomized clinical trials for EOC have included OCCC; therefore, current treatment for OCCC is basically the same as that for other histologic types of EOC. However, the clinical characteristics of OCCC differ from those of high‐grade serous carcinoma, particularly for chemosensitivity, and there is a need to develop new treatment for OCCC. The molecular background of OCCC has unique features: tumors are usually negative for p53 mutations and positive for ARID1A and/or PIK3CA mutations, whereas p53 mutations are common in high‐grade serous or endometrioid carcinomas. These features may help in development of new treatment for OCCC. In this review, we described the current evidence for treatment of OCCC, including surgery, radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, and we discuss ongoing clinical trials and preclinical studies of new treatment approaches for OCCC.

show abstract

Clear-cell carcinoma of the ovary

Cited by 86 publications

References 14 publications

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Ovarian Clear Cell Carcinoma in Cowden Syndrome

Metastatic Ovarian Clear Cell Carcinoma in the Context of In Vitro Fertilization Pregnancy

Current and future strategies for treatment of ovarian clear cell carcinoma

Contact Info

Product

Resources

About